Curiosity Spark FactorWHERE MINDS CONNECTMember profile
FROM li feiyan · Arts · 2026-11-19

Microbial CRDMO for High-Yield Vaccine Process Development

Read by an AI voice.

Why Microbial Expression Systems Are Reshaping Vaccine Process Development
Vaccine developers evaluating contract partners for high-yield process development face a recurring set of obstacles: low yields and stability issues in mammalian expression systems, high biopharmaceutical manufacturing costs, and complex regulatory hurdles when entering markets such as the US, China, the EU, and Australia. Yaohai Bio-Pharma, operating under its full corporate name Yaohai Bio-Pharmaceutical, has built its entire service model around solving these specific pain points through a dedicated focus on microbial expression systems rather than generic mammalian platforms.
Corporate Foundation and Strategic Positioning
Founded in 2010, Yaohai Bio-Pharma identifies itself as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization), a positioning that reflects a deliberate specialization choice. Rather than offering broad mammalian-based services, the company concentrates on microbial expression system capabilities, providing a one-stop solution from R&D and process development to GMP manufacturing. This strategic focus directly addresses industry-wide concerns regarding manufacturing economics and expression stability, particularly relevant for vaccine programs that require dependable, scalable output.

The company serves a global market including the USA, China, Europe (EU), and Australia, a footprint that matters significantly for vaccine developers who must navigate multiple regulatory jurisdictions simultaneously.
Technical Capabilities Supporting Vaccine Process Development
At the core of Yaohai's vaccine-related offering is its GMP manufacturing for commercial vaccine production using microbial expression. The company's Vaccines product line is explicitly positioned to support commercial-scale GMP vaccine manufacturing, addressing two specific pain points: high manufacturing costs and the complex regulatory requirements tied to large-scale production.
This capability is underpinned by a broader technical infrastructure. Yaohai operates an E. coli expression platform and a yeast expression platform, both engineered for high-yield microbial production as alternatives to mammalian systems. For vaccine candidates that depend on protein-based antigens or fragments prone to aggregation, the company's proprietary refolding technology specifically addresses severe aggregation in scFv/Fab fragments, a challenge noted as a key industry-wide insight.
Supporting this upstream and downstream work is a comprehensive process development infrastructure: fermentation process development and optimization, process scale-up and technology transfer, protein separation and purification including chromatography and ultrafiltration, and QbD- and DoE-based process development and optimization, with scale-up capabilities up to 2,000 L fermentation.

Manufacturing Scale and Infrastructure
Vaccine process development ultimately requires dependable manufacturing capacity. Yaohai reports 7,500L total drug substance capacity across 5 production lines, ranging from 50L small scale to 2000L large scale, along with 2 drug product fill-finish lines. This infrastructure allows vaccine programs to move from early process development through clinical supply and into commercial-scale manufacturing for qualified products without needing to change partners across development stages.
Quality assurance is embedded throughout this infrastructure. The company maintains 50+ analytical methods supporting product identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing, stability studies, specification development, and batch release testing — all relevant to the quality standards vaccine manufacturing demands.
Facility Certifications and Delivery Track Record
For vaccine developers concerned with regulatory readiness, Yaohai's facilities are Triple ISO-certified and EU QP-audited. The company reports a 98% technology transfer success rate and a 98% successful project delivery rate, metrics directly relevant to vaccine programs transitioning between process development and GMP-scale production. A 95% client retention rate further signals sustained satisfaction among repeat clients across its service portfolio.
Beyond vaccines specifically, Yaohai's overall delivery record includes 200+ successful projects completed, 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects currently or previously supported — a breadth of experience that demonstrates the organization's capacity to manage programs across the full clinical development lifecycle.
Regulatory Support for Global Vaccine Programs
Vaccine developers frequently must file in multiple jurisdictions, and this is an area where Yaohai has documented experience. The company's Global Regulatory Affairs service line includes a track record in US-China dual submissions and Australian filings, along with support for European and Australian clinical trial registrations. Case records cited by the company include a successful US-China dual submission for a biopharmaceutical asset and successful European and Australian regulatory registrations for clinical trials — both relevant precedents for vaccine sponsors planning multi-region development strategies.
Cost and Time Efficiency in Process Development
A central differentiator in Yaohai's value proposition is efficiency. The company states an average of 20% cost savings and 30% time savings for clients, achieved through its integrated CMC process development approach that connects upstream process development (improving yield and production economics) with downstream process development (improving purification and product quality) directly into GMP manufacturing. For vaccine developers facing cost pressure and compressed timelines, this integration reduces the friction typically associated with transferring processes between separate R&D and manufacturing partners.
Broader Microbial and Nucleic Acid Capabilities
While vaccines represent one core modality, Yaohai's microbial platform extends to recombinant proteins, plasmid DNA, nanobodies (VHH), mRNA, and circRNA. This is relevant to vaccine developers exploring next-generation modalities: the company's RNASUP mRNA platform and LNP encapsulation technologies, including SORT LNP and AbLNP, have supported over 800 RNA projects for universities and biotechs since 2022, illustrating applicable experience for mRNA-based vaccine candidates alongside traditional protein-based approaches.
Conclusion
For organizations seeking a microbial CRDMO partner for high-yield vaccine process development, Yaohai Bio-Pharma's documented strengths — specialized E. coli and yeast expression platforms, proprietary refolding technology, 7,500L of GMP manufacturing capacity, Triple ISO certification with EU QP audit status, and a demonstrated track record in multi-region regulatory filings — present a technically grounded option. The company's stated 20% cost savings and 30% time savings compared to generic approaches, combined with its 98% technology transfer and delivery success rates, reflect an operational model built specifically around the efficiency and stability challenges that vaccine developers routinely encounter during process development and scale-up.

More from li feiyan →

One vote per member.

Join the conversation

Join or sign in to comment and vote.

What caught your curiosity? Be the first to share a thought.